COPD Biomarker Qualification Consortium (CBQC)

Download Profile PDF
At a Glance
  • Status: Active Consortium
  • Year Launched: 2011
  • Initiating Organization: COPD Foundation
  • Initiator Type: Nonprofit foundation
  • Disease focus:
    Copd
  • Location: North America

Abstract

The COPD Biomarker Qualification Consortium (CBQC) pools data related to biomarkers from many clinical trials conducted by pharmaceutical companies, academia, and the National Heart, Lung, and Blood Institute to create a sufficiently large data set to allow for evidence that supports qualification by the U.S. Food and Drug Administration and the European Medicines Agency. CBQC is considering a range of biomarkers that measure quality of life, exercise capacity, specific measures of lung function (such as hyperinflation), and blood tests that report inflammation in chronic obstructive pulmonary disease (COPD).

Mission

CBQC’s mission is to qualify biomarkers for COPD to provide measures that could facilitate the development of new treatments.  

Consortium History

2011: CBQC created as a result of COPD Biomarker Qualification Workshop.

Data Sharing

The results of the biomarker qualification will be made public; however, the database will not be made public to protect patient information. The database will be available to regulatory authorities.

Sponsors & Partners

COPD Foundation

Last Updated: 04/14/2016
The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.
Register your consortium  
All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.